WASF3 and triple-negative breast carcinoma: The findings of the present study concerning NSCLC have been corroborated by similar findings in breast cancer patients; Kulkarni et al (21) observed that WASF3 expression was increased in the tumors of patients who developed distant metastases and markedly upregulated in the more aggressive triple-negative breast cancer patients.